Literature DB >> 34222617

Underutilization of societal guidelines: occasional or widespread?

Richard Kozarek1.   

Abstract

Entities:  

Year:  2021        PMID: 34222617      PMCID: PMC8211483          DOI: 10.1055/a-1399-8891

Source DB:  PubMed          Journal:  Endosc Int Open        ISSN: 2196-9736


× No keyword cloud information.
The current publication by Issak et al, “Prophylactic rectal indomethacin and pancreatic duct stents (PPS) for prevention of post-ERCP pancreatitis (PEP) are underutilized in average and high-risk patients undergoing ERCP” 1 , reviews 31,050 adults captured by the IBM Explorys database between 2014 and 2019. Patients were categorized by risk factors for PEP, which included female sex, age < 40 years, sphincter of Oddi dysfunction, history of acute pancreatitis, or pancreatic sphincterotomy at time of the procedure 2 . Average-risk patients had no risk factors, and patients were stratified for 0 to ≥ 3 risk factors. The database did not allow retrieval of other procedural risk factors for PEP to include multiple cannulation attempts, multiple pancreatic duct injections, pancreatic acinarization with contrast injection, or failure to use guidewire cannulation to selectively access the biliary tree; nor did it define the ERCP experience of the endoscopist or whether a trainee was involved in the procedure. The primary outcome of the study was to define the incidence of nonsteroidal anti-inflammatory drug (NSAID) or pancreatic stent use in an attempt to decrease PEP. Secondary outcomes were prophylaxis for and incidence of PEP contingent upon number of risk factors. Not surprising was that as the number of risk factors increased, so too did PEP. What perhaps was surprising in this study was that only one-third of all patients undergoing ERCP received PEP prophylaxis. This included 82.4 % receiving rectal indomethacin and 12.4 % who had placement of a prophylactic pancreatic stent (PPS). Despite multiple limitations of this study, to include its retrospective review of a database that provides a suboptimal diagnosis of PEP and fails to account for most procedural and endoscopist risk factors, it nevertheless is very clear that endoscopists in this database failed to adhere to societal guidelines to reduce the risk of PEP in two-thirds of the patients. These include recommendations by the ASGE and ESGE as well as from Japan 3 4 5 . Given the prospective and randomized controlled trials demonstrating the efficacy of rectal NSAIDs to reduce the risk and severity of PEP in average as well as high-risk patients 6 7 8 9 10 11 , these societal guidelines are clear that all patients undergoing ERCP should receive periprocedural rectal NSAIDS. Moreover, although there are no formal societal guidelines that recommend use of PPS, their use has been associated with a decreased risk of PEP in patients undergoing complex ERCP 10 . Such stents were placed in 4.3 % of these patients in this series, and only 1.6 % of these patients had both PPS and rectal indomethacin. Whether this “belt and suspenders” prophylaxis proves more effective than either technique alone to prevent PEP is unknown at the time but is currently undergoing study in the National Institutes of Health-sponsored stent vs indomethacin study (SVI). So, what good are societal guidelines, most derived from a graded review of the literature, supplemented by expert opinion 12 13 14 15 , if they are not followed? And is this underutilization occasional or systemic? Furthermore, are there any repercussions of failure to follow them other than the potential for suboptimal patient outcomes? In other words, do they have any teeth such that failure to follow them leads to failure to become privileged in an endoscopy unit or censure of privilege by ignoring one or more specific guidelines? Is there a financial incentive to adhere to guidelines, or is there actually a perverse incentive to overuse certain endoscopic procedures despite guidelines? The above are complex issues and perhaps beyond the scope of this editorial. Guideline adherents point to improved patient outcomes and standardization of care, whereas those who fail to heed them cite contradictory recommendations, the continued evolution of guideline recommendations, and their profusion in all aspects of endoscopic practice leading to “cookbook care.” As such, we have evolved practice patterns to ensure compliance with screening and potentially banding cirrhotic patients to prevent an index variceal bleed 16 . We recommend screening of virtually all patients for colorectal cancer and variable surveillance intervals based upon initial findings, genetics, and family history 17 18 19 20 21 . We screen and variably surveille for Barrett’s esophagus and undertake or refer patients to experienced colleagues for endoscopic mucosal resection or endoscopic submucosal dissection with finding of high-grade dysplasia and high-risk patients with superficial malignancy 22 23 24 25 26 . We recognize that chromo-endoscopy finds more dysplasia with fewer biopsies then white light endoscopy with or without the ability to magnify the image or filter the wavelength, but without formal societal guidelines, it is the minority of endoscopists who utilize it in screening patients with inflammatory bowel disease 27 28 29 . However, there are guidelines to screen for gastric malignancy 30 , to perform and interpret capsule endoscopy 31 appropriately, and about the appropriate application of endoscopic ultrasound 32 , as well as dozens of other endoscopic procedures. Not to mention procedural sedation, the appropriate cessation intervals for various anticoagulants and the indications for periprocedural antibiotics. That brings us back to the Issak et al manuscript in the current issue of Endoscopy International Open 1 . Was failure to treat patients undergoing ERCP with NSAIDs or PSP related to skepticism about the results of previous studies, ignorance of those studies, or as the authors suggest, inadequate access to rectal indomethacin (or skill set to place a PSP)? It is clear, at least in this instance, that underutilization of societal guidelines is widespread and that this failure can be associated with significant iatrogenic patient illness on the one hand and cumulative hospitalization-related expense, on the other. Without definitive consequences for non-adherence, guidelines are just that, guidelines.
  31 in total

1.  Predictors of Poor Adherence of US Gastroenterologists with Colonoscopy Screening and Surveillance Guidelines.

Authors:  Heba Iskandar; Yan Yan; Jill Elwing; Dayna Early; Graham A Colditz; Jean S Wang
Journal:  Dig Dis Sci       Date:  2014-11-04       Impact factor: 3.199

2.  Adherence to European Society of Gastrointestinal Endoscopy recommendations of endoscopists performing small bowel capsule endoscopy in Italy.

Authors:  Emanuele Rondonotti; Cristiano Spada; Marco Pennazio; Roberto de Franchis; Sergio Cadoni; Carlo Girelli; Cesare Hassan; Riccardo Marmo; Maria Elena Riccioni; Giuseppe Scarpulla; Marco Soncini; Maurizio Vecchi; Renato Cannizzaro
Journal:  Dig Liver Dis       Date:  2018-12-10       Impact factor: 4.088

3.  Practice patterns of post-ERCP pancreatitis prophylaxis techniques in the United States: a survey of advanced endoscopists.

Authors:  Patrick Avila; Ian Holmes; Abdul Kouanda; Mustafa Arain; Sun-Chuan Dai
Journal:  Gastrointest Endosc       Date:  2019-11-16       Impact factor: 9.427

4.  Time Trends in Adherence to Surveillance Intervals and Biopsy Protocol Among Patients With Barrett's Esophagus.

Authors:  Sachin Wani; J Lucas Williams; Srinadh Komanduri; V Raman Muthusamy; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2019-10-14       Impact factor: 22.682

5.  Adherence to post-polypectomy surveillance guidelines: a systematic review and meta-analysis.

Authors:  Roupen Djinbachian; Anne-Julie Dubé; Madeleine Durand; Louopou Rosalie Camara; Benoit Panzini; Simon Bouchard; Daniel von Renteln
Journal:  Endoscopy       Date:  2019-03-25       Impact factor: 10.093

Review 6.  Performance measures for endoscopy services: A European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative.

Authors:  Roland Valori; George Cortas; Thomas de Lange; Omer Salem Balfaqih; Marjon de Pater; Pierre Eisendrath; Premysl Falt; Irfan Koruk; Akiko Ono; Nadan Rustemović; Erik Schoon; Andrew Veitch; Carlo Senore; Cristina Bellisario; Silvia Minozzi; Cathy Bennett; Michael Bretthauer; Mario Dinis-Ribeiro; Dirk Domagk; Cesare Hassan; Michal F Kaminski; Colin J Rees; Cristiano Spada; Raf Bisschops; Mathew Rutter
Journal:  United European Gastroenterol J       Date:  2018-11-04       Impact factor: 4.623

7.  How do international gastric cancer prevention guidelines influence clinical practice globally?

Authors:  Evita Gasenko; Marcis Leja; Inese Polaka; Alinta Hegmane; Raul Murillo; Dmitry Bordin; Alexander Link; Minna Kulju; Pawel Mochalski; Gidi Shani; Peter Malfertheiner; Rolando Herrero; Hossam Haick
Journal:  Eur J Cancer Prev       Date:  2020-09       Impact factor: 2.497

8.  Rectal Indomethacin Prevents Moderate to Severe Post-ERCP Pancreatitis and Death and Should Be Used Before the Procedure: A Meta-Analysis of Aggregate Subgroup Data.

Authors:  Mohammad Yaghoobi; Mohammed A Alzahrani; Julia McNabb-Baltar; Myriam Martel; Alan N Barkun
Journal:  J Can Assoc Gastroenterol       Date:  2018-03-27

9.  Pancreatic stenting to prevent post-ERCP pancreatitis: a randomized multicenter trial.

Authors:  Veit Phillip; Aldis Pukitis; Alexey Epstein; Alexander Hapfelmeier; David Haf; Miriam Schwab; Ihsan Ekin Demir; Jonas Rosendahl; Albrecht Hoffmeister; Roland M Schmid; Andreas Weber; Hana Algül
Journal:  Endosc Int Open       Date:  2019-07-03

10.  Rectal Indomethacin Is Protective against Pancreatitis after Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-Analysis.

Authors:  Xingkang He; Wenfang Zheng; Yue Ding; Xia Tang; Jianmin Si; Lei-Min Sun
Journal:  Gastroenterol Res Pract       Date:  2018-05-09       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.